Last reviewed · How we verify

NCT04652024

Effect of Anorectal Biofeedback on Encopresis in School Aged Girls After Sexual Assault

Completed NA Last updated 14 September 2021
What this trial tests

NA trial testing Anorectal manometry in Fecal Incontinence in 30 participants. Completed in 1 March 2021.

Timeline
1 November 2020
Primary endpoint
1 March 2021
1 March 2021

Quick facts

Lead sponsorBadr University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment30
Start date1 November 2020
Primary completion1 March 2021
Estimated completion1 March 2021
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Badr University

Who can join

Adults 5 to 11, female only, with Fecal Incontinence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Females who have been sexually abused anally, have a disturbed anorectal motility. They have an increased resting pressure at the lower part of the anal canal. When their rectum is suddenly distended, they tend not to have an initially increased pressure in the anal canal, and the recto-anal inhibitory reflex is markedly decreased amplitude which is caused by reflex contraction of the pelvic floor during the relaxation of the internal anal sphincter.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Anorectal manometry

Trials testing the same drug.

Other recruiting trials for Fecal Incontinence

Currently open trials in the same condition.

Other Badr University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04652024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing